Pharma & Biotech Global Week in Review 5 Aug 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

US: America’s Affordable Health Choices Act : House Energy & Commerce Committee OKs 12-year data exclusivity for biotech drugs (Patent Baristas) (Patent Docs) (FDA Law Blog) (PatentlyBIOtech) (GenericsWeb)

 
General

Pharmaceutical patent settlements under fire on both sides of the Atlantic (GenericsWeb)

Biotechnology companies at forefront of global health innovation – post 1: GlaxoSmithKline & Alnylam Pharmaceuticals (PatentlyBIOtech)

Australia: Parliamentary inquiry into gene patenting (The IP Factor)

Canada: In an economic downturn biotechnology companies should consider intangible migration (Pharmacapsules@Gowlings)

India: First VIP speaker at NUJS: Jayashree Watal on Doha and TRIPS (Spicy IP)

India: The efficacy standard – India’s new patentability criteria (IP Osgoode)

India to introduce whistle blower scheme in bid to counter spurious drugs (Spicy IP)

Japan set to allow more patents on medical inventions (Patent Baristas)

US: District Court W D Washington refuses to vacate Markman ruling following settlement: Unigen Pharmaceuticals v Walgreen (Washington State Patent Law Blog)

US: CAFC: Yellow beans are just yellow beans: In re Pod-Ners LLC (Patent Baristas)

US: Follow-on biologics news briefs (No 6. – Patent Docs)

US: America’s Affordable Health Choices Act : House Energy & Commerce Committee OKs 12-year data exclusivity for biotech drugs (Patent Baristas) (Patent Docs) (FDA Law Blog) (PatentlyBIOtech) (GenericsWeb)

US: Patents and data exclusivity: It ain’t necessarily so (Patent Docs)

US: Teva fights for biotech generics (GenericsWeb)

US bill considers access to Canadian pharmaceuticals (Pharmacapsules@Gowlings)

US: Bilski and biotechnology – an update (Holman’s Biotech IP Blog)

US: Fish & Richardson catches error in Patent Office’s PTA calculation (Patent Docs)

US: BPAI reverses rejection of metabolite claim: Ex parte Competitive Technologies, Inc (Inventive Step) (Patent Docs)

US: Prometheus and natural phenomena: Prometheus Lab v Mayo Collaborative (PATracer)

 
Products

Altace (Ramipril) – Canada: Court finds patent infringed but invalid, dismisses two actions for infringement: Sanofi v Apotex/Novopharm (Pharmacapsules@Gowlings)

Altace (Ramipril) – Canada: Court of Appeal upholds decision holding generic company not required to address patents listed on the patent register against submissions filed after it had purchased its comparator drug: Canada v Pharmascience (Pharmacapsules@Gowlings)

AndroGel (Testosterone) – US: Solvay and Watson seek to overturn FTC ruling on AndroGel (Patent Docs)

Aricept (Donepezil) / Valtre&xnbsp;– US: Apotex alleges it is injured by Ranbaxy’s inability to launch generic versions of Aricept and Valtrex on time (Pharmacapsules@Gowlings)

Avandia, Avandamet, Avandaryl (Rosiglitazone stand alone and combinations) – India: The fate of Rosiglitazone patents: Far from Rosy? (Spicy IP)

Coversyl (Perindopril) – Canada: Court of Appeal upholds Trial Division finding of patent validity and infringement: Apotex v ADIR (Pharmacapsules@Gowlings)

Cozaar (Losartan) – France: French Patent Office grants paediatric extension of French SPC for Losartan (The SPC Blog)

Cozaar/Hyzaar (Losartan) – US: FDA prevails in generic Cozaar/Hyzaar 180-day exclusivity forfeiture litigation: Teva Pharmaceuticals v Sebelius (FDA Law Blog)

Diflucan (Fluconazole) – Canada: Court dismisses Pfizer’s motion for summary judgment in s 8 NOC Regulations case: Apotex v Pfizer (Pharmacapsules@Gowlings)

Effexor (Venlafaxine) – Australia: Irreparable harm and interim injunctive relief – FCA interlocutory injunctive relief granted to pharma originator: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (PatLit)

Ethyol (Amifostine) – US: Caraco announces settlement of Ethyol ANDA patent litigation with MedImmune (SmartBrief) (Patent Docs)

Hectorol (Doxercalciferol) – US: Genzyme files patent infringement suit against Roxane over its plans to market generic Hectorol (GenericsWeb)

Levaquin (Levofloxacin) – Canada: Court of Appeal overturns applications judge’s decision, issuing prohibition order and sending back for reconsideration in appeal of NOC proceeding: Apotex v Janssen (Pharmacapsules@Gowlings)

Levitra (Vardenafil) – US: Bayer Schering files patent infringement suit over Teva’s ANDA to manufacture generic Levitra (Patent Docs)

Profender (Emodepside/Praziquantel) – UK: EWHC: Astella’s appeal dismissed, with no reference to ECJ in case concerning SPC applications for combination products: Astellas Pharma Inc v Comptroller-General of Patents (PatLit)

Provigil (Modafinil) – US: Judge restarts litigation over Cephalon’s patent deals (GenericsWeb)

Tavanic (Levofloxacin) – UK: Enantiomer of a known compound held patentable by UK Court of Appeal: Generics (UK) v Daiichi (Patents4Life)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: